Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab-Reference-Cited by-同舟云学术

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab

Published:2014-11-08 Issue:21 Volume:5 Page:10280-10292
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Falchook Gerald S¹,Wheler Jennifer J²,Naing Aung²,Jackson Edward F³,Janku Filip²,Hong David²,Ng Chaan S⁴,Tannir Nizar M⁵,Lawhorn Kristie N⁶,Huang Mei²,Angelo Laura S⁷,Vishwamitra Deeksha⁸,Hess Kenneth⁹,Howard Adrienne N²,Parkhurst Kristin L²,Amin Hesham M⁸,Kurzrock Razelle¹⁰

Affiliation:

1. Sarah Cannon Research Institute, Denver, CO 80218

2. Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030

3. Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705

4. Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

5. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

6. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

7. Department of Immunology, Allergy, and Rheumatology, The Center for Human Immunobiology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX 77030

8. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

9. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

10. Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego, San Diego, CA 92093

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted therapy for head and neck squamous cell carcinoma microenvironment;Frontiers in Medicine;2023-08-30

2. Understanding the relationship between cancer associated cachexia and hypoxia-inducible factor-1;Biomedicine & Pharmacotherapy;2023-07

3. PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma;Nature Cell Biology;2023-04-24

4. Thrombospondin-1 induction and VEGF reduction by proteasome inhibition;Heliyon;2023-02

5. Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review;Frontiers in Pharmacology;2022-12-01